A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1–associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study is a research paper published in Neuro-Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 82 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Department of Defense Neurofibromatosis Research Program
Grant: W81XWH
National Institutes of Health
Grant: P50CA165962
NCATS NIH HHS
Grant: UL1 TR002538
Department of Defense Neurofibromatosis Research Program
Grant: W81XWH-05-1-0615
NICHD NIH HHS
Grant: U54 HD090255
NCATS NIH HHS
Grant: UL1 TR001855
National Institutes of Health
Grant: 4P50CA165962-04
SPORE: Targeted Therapies for Glioma
FWCI
3.93
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals